COVID-19 Records

Attachment

Gates Package, p.65 · gates:exh:00031

Page text: p.65 · original PDF

Date
(unknown precision)
Type
attachment · document
Topics
Therapeutics and treatments
evaluation and other usages. e Anticipated December 2014 o Biocryst will make available an additional 10 treatment courses for clinical evaluation and other usages. o Biocryst will file an IND with the FDA to conduct a Phase 1 clinical trial. e January 2015 -- Biocryst will initiate enrollment into a Phase 1 clinical trial for safety. Medivector -- Favipiravir antiviral drug